By Barbara Obstoj-Cardwell. Editor
India’s Biocon announced a $3.3 billion deal to acquire the recently set up generics powerhouse Viatris’ biosimilars assets. US pharma giant Pfizer became the latest to hit a roadblock in its attempts to develop a Clostridioides difficile vaccine, (PF-06425090), reporting mixed results from a Phase III trial. Meantime, AstraZeneca and Sanofi presented positive new Phase III data on their RSV disease candidate nirsevimab last Wednesday. Also, drug developer Karyopharm suffered a setback with its endometrial p53 wild-type candidate Xpovio (selinexor).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze